Top Markets
Coin of the day
Galera Therapeutics, Inc. Galera Therapeutics, Inc.

Galera Therapeutics, Inc.

GRTX
Rangering i aksjer #33957
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
Aksjekurs
$17.15
Sist synkronisert: 2026-08-03
Markedsverdi
$6.51M
Endring (1 dag)
9.80%
Endring (1 år)
289.77%
Land
US
Handel Galera Therapeutics, Inc. (GRTX)

Kategori

Historikk for aksjesplitt for Galera Therapeutics, Inc. (GRTX)
Aksjen Galera Therapeutics, Inc. (symbol: GRTX) har gjennomgått totalt 1 aksjesplitt.
Den nyeste splittelsen skjedde Jul 13, 2026.
Én GRTX-aksje kjøpt før Jul 13, 2026 tilsvarer i dag 0.005 GRTX-aksjer.
Liste over aksjesplitt
År Splitt Multiplikator Kumulativ multiplikator
2026-07-13 1:200 x0.005 x0.005
Aksjesplitt for lignende selskaper eller konkurrenter
Selskap Antall aksjesplitt Kumulativ multiplikator Land
1 x2
US
0 -
NL
0 -
CH
0 -
KR
0 -
BE